Welcome to our book review site go-pdf.online!

You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.

Sign up

Managing Treatment-Resistant Depression
  • Language: en
  • Pages: 614

Managing Treatment-Resistant Depression

Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD. Defines Treatment-Resistant Depression and Staging Treatment Intensity Includes Treatment-Resistant Depression options for children, adolescents, geriatrics, during pregnancy, and during post-partum and menopause transitions Discusses the use of Ketamine and Esketamine for treatment-resistant depression

Neurobiology of Bipolar Disorder
  • Language: en
  • Pages: 472

Neurobiology of Bipolar Disorder

The Neurobiology of Bipolar Disorder: Road to Novel Therapeutics combines the basic neurobiology of bipolar disorder with discussions of the most recent advances in research, including the interacting pathways implicated in the pathophysiology of bipolar disorder, genetic approaches and the pharmacogenomics of bipolar disorder. The basic foundational understanding of the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research combine to aid advanced students and researchers in their understanding of bipolar disorder management using novel and fast-acting pharmaceutical and neuromodulatory approaches. Aids readers in understanding bipolar disorder in the context of NIMH Research Domain Criteria (RDoC) recommendations Covers a range of existing and potential pharmacologic and non-pharmacologic treatment options, from lifestyle adjustments to novel therapeutics Synthesizes a discussion of the cellular and molecular mechanisms underlying symptoms with clinical aspects of bipolar disorder

The Search for Antidepressants - An Integrative View of Drug Discovery
  • Language: en
  • Pages: 416

The Search for Antidepressants - An Integrative View of Drug Discovery

Major depressive disorder (MDD) is a prevalent, chronic, and recurring mental disorder. This disorder is a leading source of disability worldwide, and is associated with excess mortality rates. Currently approved antidepressants primarily enhance, or otherwise modulate monoaminergic neurotransmission, without curing the disease. Evidence indicates that only one third of patients with MDD achieve remission after treatment with a first-line antidepressant agent. Research in the past two decades has provided valuable insights into the pathophysiological understanding of MDD. However, there is an acknowledged ‘translational gap’ in the field, and few genuinely novel antidepressants have been...

Neurobiology of Depression
  • Language: en
  • Pages: 352

Neurobiology of Depression

Depression is one of the most common mental-health disorders, caused by a variety of genetic, biological, environmental, and psychological factors combined. Major depressive disorder (MDD) is typically treated with first-line antidepressant agents that primarily target monoamine neurotransmission; however, only approximately one third of patients with MDD achieve remission following a trial with such an antidepressant. Furthermore, MDD is a heterogeneous phenotype, and new frameworks such as the NIMH Research Domain Criteria (RDoC) may provide a more accurate, biologically based comprehension of the symptomatic heterogeneity of this devastating illness, and certain symptomatic clusters may b...

Interventional Psychiatry
  • Language: en
  • Pages: 622

Interventional Psychiatry

  • Type: Book
  • -
  • Published: 2024-04-16
  • -
  • Publisher: Elsevier

Recent advances in pharmacology and brain stimulation have led to the development of novel treatments for psychiatric disorders. These new advances have led to the development of a new subspeciality, Interventional Psychiatry. Interventional Psychiatry: Road to Novel Therapeutics reviews all specialized treatments including device-based interventions such as electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and deep brain stimulation (DBS). This book discusses the procedure-based pharmacologic interventions including ketamine infusion therapy and psychedelic therapies. Internationally contributed, each this book outlines the state of the field, as well as implications for training and the role of the interventional psychiatrist in treatment teams. Introduces an innovative approach combining both well-established and innovative methodologies Includes an in-depth description of putative mechanisms of action Features clinician-friendly presentation of indications, contraindications, and techniques Outlines guidelines to foster fellowships in Interventional Psychiatry

Frontiers in CNS Drug Discovery
  • Language: en
  • Pages: 653

Frontiers in CNS Drug Discovery

"Frontiers in CNS Drug Discovery" is an Ebook series devoted to publishing the latest and the most important advances in Central Nervous System (CNS) drug design and discovery. Eminent scientists write contributions on all areas of rational drug design an

Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders
  • Language: en
  • Pages: 328

Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders

  • Type: Book
  • -
  • Published: 2019-02-12
  • -
  • Publisher: Springer

This book includes a series of reviews on general aspects of biomarker use in the study of psychiatric and neurodegenerative diseases and the development of medications involved in their treatment. It describes the pros and cons of the various approaches and covers the successes and failures in this research field. It is only by a thorough understanding of the shortcomings that progress can be made. The overall goal is to facilitate the understanding and treatment of these disorders, by providing a viable mechanism of catching up with other areas of modern medicine, such as diabetes and heart disease. Finally, it is anticipated that the development and application of valid biomarker tests and the leveraging of novel drug targets will help the fields of psychiatry on neurodegenerative disorders move into the area of personalized medicine where the right patients can receive the right medication at the right time for the best possible outcome.

Linking Treatment Target Identification to Biological Mechanisms Underlying Mood Disorders
  • Language: en
  • Pages: 268
The History of Neuroscience in Autobiography
  • Language: en
  • Pages: 777

The History of Neuroscience in Autobiography

The seventh volume of The History of Neuroscience in Autobiography is a collection of autobiographical essays by distinguished senior neuroscientists in which they recount the events that shaped their lives and identify the mentors and colleagues who inspired them. The narratives provides a human dimension to the world of scientific research.

Pathology, Prevention and Therapeutics of Neurodegenerative Disease
  • Language: en
  • Pages: 302

Pathology, Prevention and Therapeutics of Neurodegenerative Disease

  • Type: Book
  • -
  • Published: 2018-09-24
  • -
  • Publisher: Springer

This book, written by a leading panel of experts in the field of neurosciences, provides a comprehensive overview of the pathology of neurodegenerative diseases as well as the preventive measures. Prevention is important due to the lack of early diagnostic markers and the limitations/ problems of treating neurodegenerative diseases